ZYME | Zymeworks Inc.

Index- P/E3.36 EPS (ttm)2.58 Insider Own0.10% Shs Outstand66.74M Perf Week2.97%
Market Cap544.82M Forward P/E- EPS next Y-1.33 Insider Trans- Shs Float53.83M Perf Month2.60%
Income172.60M PEG0.31 EPS next Q-0.47 Inst Own78.40% Short Float / Ratio10.85% / 10.22 Perf Quarter8.24%
Sales446.10M P/S1.22 EPS this Y146.40% Inst Trans-0.58% Short Interest5.84M Perf Half Y12.31%
Book/sh7.10 P/B1.22 EPS next Y22.70% ROA36.00% Target Price14.07 Perf Year24.21%
Cash/sh5.42 P/C1.60 EPS next 5Y11.00% ROE50.50% 52W Range4.11 - 10.80 Perf YTD10.31%
Dividend- P/FCF5.07 EPS past 5Y42.60% ROI24.30% 52W High-19.72% Beta0.93
Dividend %- Quick Ratio6.30 Sales past 5Y51.50% Gross Margin- 52W Low110.95% ATR0.48
Employees304 Current Ratio6.30 Sales Q/Q1756.90% Oper. Margin39.40% RSI (14)46.04 Volatility4.78% 5.46%
OptionableYes Debt/Eq0.00 EPS Q/Q69.20% Profit Margin38.70% Rel Volume0.37 Prev Close8.49
ShortableYes LT Debt/Eq0.00 EarningsMay 08 AMC Payout0.00% Avg Volume571.42K Price8.67
Recom1.90 SMA20-4.45% SMA50-4.41% SMA20010.91% Volume210,612 Change2.12%
Date Action Analyst Rating Change Price Target Change
Mar-21-23Resumed Wells Fargo Overweight $12
Jan-04-23Reiterated H.C. Wainwright Neutral $10 → $8
Dec-20-22Upgrade Jefferies Hold → Buy $7.70 → $11
Nov-01-22Downgrade H.C. Wainwright Buy → Neutral $40 → $8
Oct-21-22Downgrade SVB Leerink Outperform → Mkt Perform $8
Oct-04-22Resumed Wells Fargo Overweight $45 → $9
May-05-22Upgrade Guggenheim Neutral → Buy $14
Mar-15-22Initiated Evercore ISI Outperform $15
Dec-10-21Upgrade SVB Leerink Mkt Perform → Outperform
Nov-17-21Resumed Guggenheim Neutral
Jun-02-23 06:41PM
Jun-01-23 08:30AM
May-18-23 08:30AM
May-08-23 04:05PM
May-01-23 08:30AM
04:05PM Loading…
Apr-18-23 04:05PM
Apr-17-23 08:30AM
Apr-10-23 08:30AM
Apr-03-23 08:30AM
Mar-14-23 04:30PM
Mar-07-23 04:05PM
Feb-28-23 08:30AM
Feb-21-23 08:30AM
Jan-25-23 08:30AM
Jan-19-23 07:45AM
04:15PM Loading…
Jan-04-23 04:15PM
Dec-21-22 07:30AM
Dec-19-22 07:00AM
Dec-14-22 04:15PM
Dec-09-22 08:00AM
Dec-05-22 08:30AM
Nov-29-22 08:30AM
Nov-24-22 12:20PM
Nov-22-22 09:55AM
Nov-21-22 12:22PM
Nov-08-22 05:45PM
04:22PM Loading…
Nov-02-22 10:00AM
Nov-01-22 10:01AM
Oct-31-22 04:42PM
Oct-21-22 01:35PM
Oct-20-22 01:36PM
Oct-19-22 11:08AM
Oct-18-22 08:30AM
Oct-13-22 07:00AM
Oct-07-22 04:15PM
Oct-04-22 08:30AM
Oct-03-22 08:30AM
Sep-29-22 07:30AM
Sep-26-22 04:15PM
Sep-16-22 08:30AM
Sep-13-22 09:34AM
Sep-08-22 04:15PM
Sep-04-22 06:05PM
Aug-04-22 08:35PM
Aug-01-22 08:30AM
Jul-27-22 08:45AM
Jul-25-22 08:30AM
Jul-22-22 08:30AM
Jul-21-22 08:30AM
Jul-15-22 08:00AM
Jun-27-22 08:30AM
Jun-10-22 09:57AM
May-27-22 09:57AM
May-26-22 05:00PM
May-20-22 03:13PM
May-19-22 01:00PM
May-04-22 06:25PM
May-03-22 03:27PM
May-02-22 08:30AM
Apr-29-22 10:53AM
Apr-28-22 09:00PM
Apr-27-22 04:15PM
Apr-19-22 04:15PM
Apr-14-22 06:40AM
Apr-06-22 09:26AM
Apr-05-22 04:01PM
Apr-01-22 08:30AM
Mar-03-22 08:30AM
Feb-28-22 06:37AM
Feb-24-22 06:20PM
Feb-17-22 03:02PM
Feb-15-22 05:25PM
Feb-08-22 04:15PM
Feb-03-22 04:15PM
Feb-01-22 04:49AM
Jan-31-22 12:05PM
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include Zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, colorectal, and endometrial cancers; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. The company has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
EcoR1 Capital, LLC10% OwnerMar 28Buy8.00200,0001,600,00010,087,473Mar 30 05:47 PM
Klompas Neil APresident & COOMar 10Option Exercise0.005,208020,009Mar 14 05:00 PM
Klompas Neil APresident & COOMar 10Sale7.832,97723,29817,032Mar 14 05:00 PM
EcoR1 Capital, LLC10% OwnerJan 20Buy9.88163,4001,615,0959,887,473Jan 23 06:00 PM
EcoR1 Capital, LLC10% OwnerJan 19Buy9.49144,1001,367,6399,724,073Jan 23 06:00 PM
EcoR1 Capital, LLC10% OwnerJan 18Buy10.00203,0002,029,0469,579,973Jan 18 06:27 PM
EcoR1 Capital, LLC10% OwnerJan 17Buy9.80440,0004,313,8489,376,973Jan 18 06:27 PM
EcoR1 Capital, LLC10% OwnerJan 13Buy9.81342,1003,354,6338,936,973Jan 18 06:27 PM
EcoR1 Capital, LLC10% OwnerJan 11Buy7.87106,300836,9118,594,873Jan 12 04:47 PM
EcoR1 Capital, LLC10% OwnerJan 10Buy7.65920,0007,037,1728,488,573Jan 12 04:47 PM
Astle ChristopherSVP & Chief Financial OfficerDec 12Option Exercise0.001,55002,220Dec 14 08:00 PM
Astle ChristopherSVP & Chief Financial OfficerDec 12Sale6.018875,3311,333Dec 14 08:00 PM
Josephson NeilChief Medical OfficerNov 10Option Exercise0.005,885016,924Nov 14 09:41 PM
Josephson NeilChief Medical OfficerNov 10Sale8.102,47520,04514,449Nov 14 09:41 PM